Genomic carrier screening can identify more disease-associated variants than existing carrier screening methodologies, but its utility from patients' perspective is not yet established. A randomized controlled trial for preconception genomic carrier screening provided an opportunity to understand patients' decisions about whether to accept or decline testing. We administered a survey to potential genomic carrier screening recipients who declined participation (N = 240) to evaluate their reasons for doing so. Two thirds of women declined participation. We identified major themes describing reasons these individuals declined to participate; the most common were time limitation, lack of interest, not wanting to know the information, and potential cause of worry or anxiety. Most women eligible for genomic carrier screening indicated that their reasons for opting out were due to logistical issues rather than opposing the rationale for testing. As expanded carrier screening and genomic sequencing become a more routine part of clinical care, it is anticipated there will be variable uptake from individuals for this testing. Thus, the advancement of clinical carrier screening from single genes, to expanded screening panels, to an exome- or genome-wide platform, will require approaches that respect individual choice to receive genetic testing for reproductive risk assessment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601030PMC
http://dx.doi.org/10.1007/s10897-017-0074-yDOI Listing

Publication Analysis

Top Keywords

carrier screening
32
genomic carrier
16
screening
9
carrier
8
expanded carrier
8
declined participation
8
genomic
5
reasons
4
reasons declining
4
declining preconception
4

Similar Publications

Targeting CHEK1: Ginsenosides-Rh2 and Cu2O@G-Rh2 nanoparticles in thyroid cancer.

Cell Biol Toxicol

January 2025

Department of Radiology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China.

Thyroid cancer (THCA) is an increasingly common malignant tumor of the endocrine system, with its incidence rising steadily in recent years. For patients who experience recurrence or metastasis, treatment options are relatively limited, and the prognosis is poor. Therefore, exploring new therapeutic strategies has become particularly urgent.

View Article and Find Full Text PDF

Background: Familial hyperlipidemia (familial hypercholesterolemia, FH) is an autosomal genetic disorder. It includes type heterozygous familial hyperlipidemia (heterozygous familial hypercholesterolemia). HeFH is mainly caused by mutations in the LDLR, APOB, and PCSK9 genes and is characterized by elevated plasma low-density lipoprotein cholesterol levels.

View Article and Find Full Text PDF

Background: Hemoglobin G-Siriraj is a rare hemoglobin variant caused by a β-globin gene mutation (HBB: c.22G>A). The focus of this paper is aimed mainly at the chromatographic and electrophoretic properties of hemoglobin G-Siriraj for a presumptive identification.

View Article and Find Full Text PDF

Unlabelled: Carbapenem-resistant Enterobacterales (CRE) are divided into two distinct groups: carbapenemase-producing (CPE) and non-carbapenemase-producing (non-CPE). The population of non-CPE growing on CPE selective plates during routine screening is usually not reported and is not well defined. This study aimed to characterize non-CPE isolates growing on those plates.

View Article and Find Full Text PDF

Ultrasensitive photoelectrochemical detection of cancer markers based on heterojunctions constructed from BiO star-like flower nanoclusters and CdS hollow nanorods.

Talanta

January 2025

Department of Chemistry and Laboratory for Preparation and Application of Ordered Structural Materials of Guangdong Province, Shantou University, Shantou, Guangdong, 515063, P.R. China; Guangdong Engineering Technology Research Center of Offshore Environmental Pollution Control, Shantou, Guangdong, 515063, P.R. China; Analysis & Testing Center, Shantou University, Shantou, Guangdong, 515063, P.R. China. Electronic address:

CYFRA21-1 is a tumor marker for lung cancer, and its rapid and accurate detection can provide evidence for the early diagnosis of lung cancer. In this work, Bi-Fe turnbull blue analogues (Bi-Fe-TBA) were synthesized by the self-templating method. BiO-SFNs was prepared by simple oxidation in air using Bi-Fe-TBA as a template.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!